ArticleInternational journal of cardiology. Congenital heart disease2025
Prognostic implications of heart failure rehospitalization in adults with CHD & clinical benefits of medical therapy.
Article in International journal of cardiology. Congenital heart disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The risk factors for heart failure (HF) rehospitalization, and the effect of guideline directed medical therapy (GDMT) are poorly understood in adults with congenital heart disease (ACHD). We aimed to describe the outcomes of HF hospitalization and to assess the clinical benefits of GDMT for HF. Methods: We conducted a retrospective cohort study of ACHD hospitalized for HF at Mayo Clinic from 2003 to 2023. Cox proportional hazard models were used to determine the predictors of HF rehospitalization and all-cause mortality, and to assess the association between death and GDMT, as measured by the Heart Failure Collaborative score. Results: Of the 324 patients, 164 were rehospitalized for HF and 149 died. The 10-year cumulative incidence of rehospitalization was 75.8 % (95 % CI 70.1 %-81.5 %), and the 10-year survival rate from mortality was 47.3 % (95 % CI 40.9 %-54.7 %). Chronic kidney disease (HR 1.46, 95 % CI 1.06-2.01, p = 0.021) and Fontan physiology (HR 1.59, 95 % CI 1.02-2.49, p = 0.043) were associated with HF rehospitalization. HF rehospitalization within 1 year was associated with nearly a 3-fold increased risk of mortality (HR 2.88, 95 % CI 2.00-4.15, p < 0.001). The HFC score was associated with a lower risk of all-cause mortality (HR 0.77, 95 % CI 0.62-0.95, p = 0.016) in the subgroup of patients with reduced ejection fraction. Conclusions: Among adults with CHD hospitalized for HF, half of the patients were rehospitalized for HF. Rehospitalization within 1 year of the index HF hospitalization was associated with mortality. The use of GDMT for HF was associated with improved survival in patients with reduced ejection fraction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.